Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
Status:
Active, not recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Explore the efficacy and safety of Envafolimab in first line treatment of elderly patients
with locally advanced or metastatic non-small cell lung cancer with high PD-L1 expression,
view to providing better treatment options for elderly patients with high PD-L1 expression
and improving the survival and prognosis of patients .
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University